Circulating TDEs with “high FasL” expression were associated with advanced stage (T3/T4) tumors in head and neck cancer patients, while TDEs with “low FasL” levels were associated with early stage (T1/T2) tumors.147 TDEs from the serum of patients with active disease, primary HNSCC without prior treatment and recurrence HNSCC, also expressed higher FasL levels than those of patients with no evidence of disease or normal controls.152 These preliminary findings highlight the potential ability of TDEs to predict disease progression. Here, FASLG is linked to head and neck cancer.